Tag: Upper GI Cancer

Adding docetaxel to standard-of-care does not improve outcomes in gastric cancer

Presented By
Dr Anant Ramaswamy, Tata Memorial Centre, India
Trial
Phase 3, DOC-GC
Conference
ASCO GI 2024
Type
News article

13 February 2024 14:37

Thoracoscopic oesophagectomy non-inferior to open surgery in thoracic oesophageal cancer

Presented By
Prof. Hiroya Takeuchi, Hamamatsu University, Japan
Trial
Phase 3, JCOG1409
Conference
ASCO GI 2024
Type
News article

13 February 2024 14:33

KEYNOTE-590: 5-Year outcomes confirm benefit of pembrolizumab in oesophageal cancer

Presented By
Prof. Manish Shah, Weill Cornell Medicine, NY, USA
Trial
Phase 3, KEYNOTE-590
Conference
ASCO GI 2024
Type
News article

13 February 2024 14:26

New standard-of-care for locally advanced oesophageal squamous cell carcinoma?

Presented By
Prof. Yin Li, National Cancer Center, China
Trial
Phase 3, ESCORT-NEO
Conference
ASCO GI 2024
Type
News article

13 February 2024 14:23

MATTERHORN: FLOT plus durvalumab leads to high pCR rate in gastric cancer

Presented By
Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, NY, USA
Trial
Phase 3, MATTERHORN
Conference
ASCO GI 2024
Type
News article

13 February 2024 14:19

SKYSCRAPER-08: Adding tiragolumab to oesophageal cancer regimen improves outcomes

Presented By
Prof. Chih-Hung Hsu, National Taiwan University Hospital, Taiwan
Trial
Phase 3, SKYSCRAPER-08
Conference
ASCO GI 2024
Type
News article

13 February 2024 14:17

CheckMate 648: More quality time for patients with oesophageal cancer on nivolumab

Presented By
Prof. Ian Chau, Royal Marsden Hospital, UK
Trial
Phase 3, CheckMate 648
Conference
ASCO GI 2024
Type
News article

13 February 2024 14:13

CheckMate 649: Nivolumab plus chemotherapy continues to deliver efficacy benefit in gastric cancer

Presented By
Dr Kohei Shitara, National Cancer Center Hospital East, Japan
Trial
Phase 3, CheckMate 649
Conference
ASCO GI 2024
Type
News article

13 February 2024 14:03

Modified FLOT regime outperforms FOLFOX in advanced/metastatic gastric/gastroesophageal junction adenocarcinoma

Presented By
Prof. Aziz Zaanan, Université Paris Cité, France
Trial
Phase 3, GASTROFOX
Conference
ESMO 2023
Type
Peer-reviewed article

19 December 2023 10:30

Epinephrine boosts efficiency in gastric ESD

Presented By
Dr Hon Chi Yip, The Chinese University of Hong Kong, China
Conference
UEGW 2023
Type
Peer-reviewed article

7 December 2023 14:38

AI detects gastric cancer with high accuracy in common blood tests

Presented By
Mr Tsz Chun Bryan Wong, Hong Kong University of Science and Technology, Hong Kong
Conference
ASCO 2023
Type
Peer-reviewed article

2 August 2023 09:34

Zolbetuximab plus mFOLFOX6 successful in CLDN18.2-positive subgroup of gastric cancer

Presented By
Dr Kohei Shitara, National Cancer Center Hospital East, Japan
Trial
Phase 3, SPOTLIGHT
Conference
ASCO GI 2023
Type
Peer-reviewed article

17 March 2023 08:31

Regorafenib offers survival benefit for patients with pre-treated gastric cancer

Presented By
Prof. Nick Pavlakis, University of Sydney, Australia
Trial
Phase 3, INTEGRATE IIa
Conference
ASCO GI 2023
Type
Peer-reviewed article

17 March 2023 08:24

Radiotherapy or not in locally advanced oesophageal or junctional cancer?

Presented By
Prof. Maeve Lowery, St James’s Hospital, Ireland
Trial
Phase 3, Neo-AEGIS
Conference
ASCO GI 2023
Type
Peer-reviewed article

17 March 2023 08:20

Neoadjuvant immunotherapy is safe and efficacious in a phase 2 gastric cancer trial

Presented By
Dr Filippo Pietrantonio, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy
Trial
Phase 2, INFINITY
Conference
ASCO GI 2023
Type
Peer-reviewed article

17 March 2023 08:19

S-1 adjuvant chemotherapy: 4 or 8 courses in stage 2 gastric cancer?

Presented By
Dr Souya Nunobe, Cancer Institute Hospital, Japan
Trial
Phase 3, OPAS-1
Conference
ASCO GI 2023
Type
Peer-reviewed article

17 March 2023 08:18

LATG/LAPG demonstrates excellent long-term efficacy in stage 1 gastric cancer

Presented By
Dr Shinichi Sakuramoto, Saitama Medical University International Medical Center, Japan
Trial
JCOG1401
Conference
ASCO GI 2023
Type
Peer-reviewed article

17 March 2023 08:15

3-year follow-up data confirms benefits of nivolumab plus chemotherapy

Presented By
Dr Yelena Janjigian, Memorial Sloan Kettering Cancer, NY, USA
Trial
Phase 3, CheckMate 649
Conference
ASCO GI 2023
Type
Peer-reviewed article

17 March 2023 08:10

Long-term results for nivolumab plus chemotherapy and nivolumab plus ipilimumab in oesophageal cancer

Presented By
Dr Ken Kato, National Cancer Center Hospital, Japan
Trial
Phase 3, CheckMate 648
Conference
ASCO GI 2023
Type
Peer-reviewed article

17 March 2023 08:02

Promising phase 2 results for HER-Vaxx in gastric cancer

Presented By
Dr Tanuj Chawla, Tata Medical Center, India
Trial
Phase 2, HERIZON
Conference
ASCO GI 2023
Type
Peer-reviewed article

17 March 2023 08:00

Chemo-immunotherapy in gastric cancer is more effective when administered in parallel

Presented By
Prof.  Sylvie Lorenzen, Klinikum rechts der Isar, TU München, Germany
Trial
Phase 2, Moonlight
Conference
ESMO 2022
Type
Peer-reviewed article

16 November 2022 17:31

Substantial increase of oesophageal cancer prevalence in the middle-aged

Presented By
Prof. Bashar J. Qumseya, University of Florida, FL, USA
Conference
DDW 2022
Type
News article

14 June 2022 22:39

EMR versus ESD in oesophageal cancer

Presented By
Dr Vani Konda, Baylor University Medical Center, TX, USA
Conference
ASCO GI 2022
Type
Peer-reviewed article

21 March 2022 11:23

Pre-operative chemoradiation versus peri-operative chemotherapy for oesophageal cancer

Presented By
Prof. Karyn Goodman, Icahn School of Medicine at Mount Sinai, NY, USA
Conference
ASCO GI 2022
Type
Peer-reviewed article

21 March 2022 11:22

AK104 plus chemotherapy promising first-line option for gastric cancer

Presented By
Dr Jiafu Ji, Beijing Cancer Hospital, China
Trial
Phase 1/2, AK104-201
Conference
ASCO GI 2022
Type
Peer-reviewed article

21 March 2022 11:19

DESTINY-Gastric01: OS benefit of T-DXd over chemotherapy for HER2-positive gastric cancer

Presented By
Dr Kensei Yamaguchi, Cancer Institute Hospital of JFCR, Japan
Trial
Phase 2, DESTINY-Gastric01
Conference
ASCO GI 2022
Type
Peer-reviewed article

21 March 2022 11:17

The emerging role of AI in gastroesophageal cancer

Presented By
Dr Wai Leung, University of Hong Kong, China
Conference
ASCO GI 2022
Type
Peer-reviewed article

21 March 2022 11:15

DCF outperforms standard-of-care for locally advanced oesophageal cancer

Presented By
Dr Ken Kato, National Cancer Center Hospital, Japan
Trial
Phase 3, JCOG1109, NExT
Conference
ASCO GI 2022
Type
Peer-reviewed article

21 March 2022 11:13

Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome

Presented By
Dr Kohei Shitara, National Cancer Center Hospital East, Japan; Dr Yu Sunakawa, St. Marianna University School of Medicine, Japan
Trial
Phase 3, CheckMate 649, DELIVER
Conference
ASCO GI 2022
Type
Peer-reviewed article

21 March 2022 11:11

Updates on pembrolizumab for oesophageal and gastric cancer

Presented By
Dr Jean-Philippe Metges, CHU Brest, France; Dr Zev Wainberg, University College Los Angeles, CA, USA
Trial
Phase 3, KEYNOTE-590, KEYNOTE-062
Conference
ASCO GI 2022
Type
Peer-reviewed article

21 March 2022 11:08

ASCO GI 2022 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
ASCO GI 2022

8 February 2022 12:37

Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer

Presented By
Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, NY, USA
Trial
Phase 3, CheckMate649
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:41

HIPEC in gastric cancer with peritoneal metastases

Presented By
Prof. Beate Rau, Charité University Hospital Berlin, Germany
Trial
Phase 3, GASTRIPEC I
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:41

ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer

Presented By
Dr Alexander Stein, University Cancer Center Hamburg, Germany
Trial
Phase 2, INTEGA
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:39

ESMO 2021 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Trial
DESTINY-Breast03, MONALEESA-2, KEYNOTE-716, CASPIAN, CheckMate-649, Impower010
Conference
ESMO 2021

4 October 2021 09:27

Benefit of both I-O/chemo combo and I-O/I-O combo over chemotherapy alone in oesophageal squamous cell cancer

Presented By
Dr Ian Chau, Royal Marsden Hospital, UK
Trial
Phase 3, CheckMate 648
Conference
ASCO 2021
Type
Peer-reviewed article

12 August 2021 20:12

Benefit of I-O/chemo combo over chemotherapy alone in advanced GC/GEJC/EAC

Presented By
Prof. Markus Moehler, Mainz University Clinic, Germany
Trial
Phase 3, CheckMate 649
Conference
ASCO 2021
Type
Peer-reviewed article

12 August 2021 19:15

Perioperative chemotherapy and neoadjuvant multimodality therapy appear equally effective

Presented By
Prof. John Reynolds, Trinity St James Cancer Institute, Ireland
Trial
Phase 3, Neo-AEGIS
Conference
ASCO 2021
Type
Peer-reviewed article

12 August 2021 13:18

Bemarituzumab response for gastric/GEJ cancers correlates with FGFR2b levels

Presented By
Prof. Zev Wainberg, UCLA, USA
Trial
Phase 2, FIGHT
Conference
ASCO GI 2021
Type
Peer-reviewed article

12 March 2021 11:50

Gut microbiome DELIVERs nivolumab forecast in gastric cancer

Presented By
Prof. Yu Sunakawa, St Marianna University School of Medicine, Kanagawa, Japan
Trial
DELIVER
Conference
ASCO GI 2021
Type
Peer-reviewed article

12 March 2021 11:47

OS benefit for trifluridine/tipiracil in advanced gastric cancer from third-line onward

Presented By
Prof. Josep Tabernero, Vall d'Hebron Institute of Oncology, Spain
Trial
TAGS
Conference
ASCO GI 2021
Type
Peer-reviewed article

12 March 2021 11:44

Neoadjuvant chemotherapy does not increase perioperative complications in thoracic oesophageal cancer

Presented By
Prof. Kazuo Koyanagi, National Cancer Center, Japan
Trial
Phase 3, JCOG 1109
Conference
ASCO GI 2021
Type
Peer-reviewed article

12 March 2021 11:42

Adjuvant nivolumab: good quality-of-life

Presented By
Prof. Eric Van Cutsem, University of Leuven, Belgium
Trial
Phase 3, CheckMate 577
Conference
ASCO GI 2021
Type
Peer-reviewed article

12 March 2021 11:40

Adding docetaxel to adjuvant S-1 reduces gastric cancer relapse

Presented By
Prof. Kazuhiro Yoshida, Gifu University, Japan
Trial
Phase 2, JACCRO GC-07
Conference
ASCO GI 2021
Type
Peer-reviewed article

12 March 2021 11:38

Duloxetine ameliorates oxaliplatin-induced peripheral neuropathy

Presented By
Dr Jeffrey Chi, Northwell Health Cancer Institute, NY, USA
Conference
ASCO GI 2021
Type
Peer-reviewed article

12 March 2021 11:31

Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?

Conference
ESMO 2020
Type
Peer-reviewed article

25 November 2020 15:08

Nivolumab improves OS in advanced oesophageal cancer

Presented By
Prof. Byoung Chul Cho, Yonsei University College of Medicine, South Korea
Trial
Phase 3, ATTRACTION-3
Conference
ESMO 2019
Type
Peer-reviewed article

26 November 2019 22:19

Immunonutrition during neoadjuvant oesophagogastric cancer therapy: no benefit

Presented By
Prof. Sheraz Markar, Imperial College London, United Kingdom
Conference
UEGW 2019
Type
Peer-reviewed article

23 October 2019 16:16

FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis

Presented By
Dr Javier Sastre, Hospital ClĂ­nico San Carlos, Spain
Trial
Phase 3, VISNU-1
Conference
ASCO 2019
Type
Peer-reviewed article

15 July 2019 23:53

KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer

Presented By
Dr Josep Tabernero, Vall d’Hebron University Hospital, Spain
Trial
Phase 3, KEYNOTE-062
Conference
ASCO 2019
Type
Peer-reviewed article

15 July 2019 22:56

Neoadjuvant chemotherapy as a potential treatment option in colon cancer

Presented By
Dr Matthew T. Seymour, National Institute for Health Research Clinical Research Network, England
Trial
FOxTROT
Type
Peer-reviewed article

15 July 2019 21:58

Maintenance olaparib improved PFS in patients with BRCA+ pancreatic cancer

Presented By
Dr Hedy L. Kindler, The University of Chicago, USA
Trial
Phase 3, POLO
Conference
ASCO 2019
Type
Peer-reviewed article

15 July 2019 14:07
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com